AbbVie cuts 2024 adjusted EPS guidance by $0.04 on $82M Q3 IPR&D charge

AbbVie Inc.

2024-Q3 EPS reported $2.41 revenue$41,232,000,000

Q3 2024 acquired IPR&D & milestones expense of $82M pre-tax, reducing GAAP and adjusted EPS by $0.04.
Q3 2024 adjusted diluted EPS guidance range now $2.88–$2.92, including the charge.
Full-year 2024 adjusted diluted EPS guidance revised to $10.67–$10.87 from $10.71–$10.91.
Guidance excludes any IPR&D expense beyond Q3 2024 due to forecasting uncertainty.
Q3 2024 results are preliminary and subject to final closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.